Atrophic gastritis refers to the reduction of intrinsic gastric glands, sometimes accompanied by intestinal epithelial hyperplasia and atypical hyperplasia. Theoretically they all belong to be precancerous lesions, which means that if these lesions are not treated, some of them may develop into gastric cancer, and according to the literature, up to 5% of patients may develop into cancer. Even if a small percentage of people develop cancer, it is a long process. Many elderly people develop atrophic changes in the stomach, and patients who have had erosive gastritis or ulcers in the past can also develop intestinal epithelial metaplasia when the lesions heal, i.e., the mucosa of the intestine grows over the stomach. Therefore, patients diagnosed with atrophic gastritis do not need to be alarmed and only need to be reviewed by endoscopy in 1-2 years. Therefore, it is important that patients diagnosed with atrophic gastritis be evaluated by an experienced physician. When severe heterogeneous hyperplasia develops in atrophic gastritis, one should be alert and, if necessary, the lesion can be removed endoscopically directly at the same time as the gastroscopy, without the need for surgery or chemotherapy. Therefore, the development of atrophic gastritis to gastric cancer can be monitored. Certain drugs are currently claimed to prevent cancer, but the evidence is insufficient. Therefore, if there are no symptoms of atrophic gastritis, long-term medication is not recommended. The most important thing is to review the endoscopy regularly to prevent the disease from developing. Therefore, there is no need to panic about atrophic gastritis, and there is no need to go around and take medication indiscriminately.